AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
LAMIVUDINE AND ZIDOVUDINE
6 registrations across 3 African markets— 4 active
Markets with LAMIVUDINE AND ZIDOVUDINE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Lamivudine and Zidovudine USP 150 mg/300 mg Film-Coated Tablet | 🇰🇪Kenya | Hetero Labs Limited | active | Jul 2031 |
| LAMIVUDINE-ZIDOVUDINE-150/300 150MG/300MG TABLET. TABLET. | 🇲🇼Malawi | — | expired | Jun 2021 |
| LAMIVUDINE&ZIDOVUDINE 150/300MG TABLET TABLET | 🇲🇼Malawi | — | expired | Jun 2016 |
| Lamivudine/Zidovudine Tablets for Oral Suspension Tablets | 🇹🇿Tanzania | Cipla Limited | active | — |
| Lamivudine + Zidovudine Tablets | 🇹🇿Tanzania | Mylan Laboratories Limited | active | — |
| Lamivudine/Zidovudine Dispersible Tablets 30 mg /60 mg Tablet, Dispersible | 🇹🇿Tanzania | Mylan Laboratories Limited | active | — |
LAMIVUDINE AND ZIDOVUDINE in Africa — Regulatory Overview
LAMIVUDINE AND ZIDOVUDINE is registered across 3 African markets with 6 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tanzania, Malawi, Kenya. AfricaRegulatory refreshes this data daily from official government sources.
Of the 6 registrations, 4 (67%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.